Goldman Sachs’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $121K | Sell |
|
|||||
|
2025
Q1 | $119K | Buy |
|
|||||
|
2024
Q4 | $189K | Buy |
|
|||||
|
2024
Q3 | $197K | Buy |
|
|||||
|
2024
Q2 | $285K | Buy |
|
|||||
|
2024
Q1 | $320K | Sell |
|
|||||
|
2023
Q4 | $297K | Buy |
|
|||||
|
2023
Q3 | $209K | Buy |
|
|||||
|
2023
Q2 | $107K | Sell |
|
|||||
|
2023
Q1 | $282K | Buy |
|
|||||
|
2022
Q4 | $95.2K | Sell |
|
|||||
|
2022
Q3 | $144K | Sell |
|
|||||
|
2022
Q2 | $232K | Buy |
|
|||||
|
2022
Q1 | $166K | Sell |
|
|||||
|
2021
Q4 | $1.41M | Buy |
|
|||||
|
2021
Q3 | $271K | Sell |
|
|||||
|
2021
Q2 | $533K | Sell |
|
|||||
|
2021
Q1 | $1.89M | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $2.51M | Buy |
|